Vol. 9 Issue 1 (2016)

Обложка журнала

PDF downloadDownload the whole Issue

 

ORIGINAL ARTICLES

Analysis of the indicators of vascular remodeling after coronary bypass surgery depending on risk factors and comorbidities. Abzalova G.F., Mayanskaya S.D., Latipova Z.K., Akhtereev R.N. P.7

About the relationship of pain, breathlessness, quality of life in patients with chronic heart failure of ischemic genesis. Abrosimov V.N., Zhukova L.A., Glotov S.I., Melnikova G.N. P.13

Analysis of medical representatives' activities directed to physicians in Egypt. Bahlol M.M., Lagutkina T.P. P.17

Respiratory diseases in Tatarstan: perennial epidemiological analysis. Vafin A.Yu., Vizel A.A., Sherputovsky V.G., Lysenko G.V., Kolgin R.A., Vizel I.Yu., Shaymuratov R.I., Amirov N.B. P.24

Association of oxidative metabolism phenotype and clinical efficacy of proton pump inhibitors in patients with gastroesophageal reflux disease. Kalugin A.A., Stepchenko A.A. P.32

Efficacy evaluation of acetylation phenotype as a criterion for predicting the course and outcome of a burn injure to the eyes. Kamilov K.M., Maksudova L.M. P.36

Standardization and adaptation review in phar-maceutical marketing promotions. Lagutkina T.P., Bahlol M.M. P.40

Study of the efficacy, safety and tolerability of the combined use of glucosamine sulfate («artrakam») and chondroitin sulfate («artradol») in patients with osteoarthritis of the knee. Lapshina S.A., Afanasievа M.A., Sukhorukova E.V., Akhtyamov I.F., Myasoutova L.I. P.46

Evaluation of endothelial dysfunction of the feto-placental complex in premature abruption of normally positioned placenta. Pakhomova Zh.E., Komilova M.S. P.52

Exercise performance and indexes of cardiopulmonary exercise testing in healthy smoking and nonsmoking young men. Postnikova L.B., Dorovskoy I.A., Kostrov V.A., Dolbin I.V., Gudim A.L. P.58

Development and implementation of computerized data management systems for assessment of diabetic foot outpatient treatment efficacy. Udovichenko O.V., Berseneva E.A., Meshkov D.O. P.64

Possibility of early diagnosis of bone metabolism disorders in postmenopausal women. Chepurnenko S.A., Mikashinovich Z.I., Bulgakova N.M. P.71

Prevalence of anxiety and depressive disorders among workers of workers of metallurgical enter-prises with arterial hypertension. Chigisova A.N., Ogarkov M.Yu., Scripchenco A.E. P.75

Chronic obstructive pulmonary disease in patients cardiology: problems of diagnosis and treatment. Shapovalova T.G., Ryabova A.Yu., Plastinina E.S., Ponomareva O.A., Shelobanova N.V., Shashina M.M., Zakirova V.B. P.79

The effectiveness of proactive telephone support in smoking cessation. Yablonsky P.K., Sukhovskaya O.A. P.84

_____

ORIGINAL ARTICLES

PDF downloadAnalysis of the indicators of vascular remodeling after coronary bypass surgery depending on risk factors and comorbidities 

UDC 616.132-089.86-031:611.132.2

DOI: 10.20969/vskm.2016.9(1).7-12

ABZALOVA GUZEL F., graduate student of the Department of hospital therapy of Kazan State Medical University, Russia, Kazan, tel. +7(906)-320-70-79, e-mail: guzelka88@bk.ru

MAYANSKAYA SVETLANA D., D. Med. Sci., рrofessor of the Department of hospital therapy of Kazan State Medical University, Russia, Kazan, tel. +7(905)-316-99-66, e-mail: Smayanskaya@mail.ru

LATIPOVA ZALIYA K., graduate student of the Department of hospital therapy of Kazan State Medical University, Russia, Kazan, tel. 8-960-051-61-69, e-mail: zaliya87@rambler.ru

AKHTEREEV RAVIL N., graduate student of the Department of cardiology of Kazan State Medical University, Russia, Kazan, tel. 8-987-212-03-00, e-mail: akhtereev@mail.ru

Abstract. The purpose of the study was to assess the nature of vascular remodeling in hypertensive and ischemic heart disease, its dynamics in the postoperative period. Material and methods. It was surveyed 104 people (25 women and 79 men) with coronary heart disease (CHD) from 39 to 85 years. All the patients underwent coronary or mammary-coronary bypass conditions, in the conditions on pump or off pump. All patients before, after 7 days and 4 months after CABG were investigated parameters of the vascular hemodynamic parameters (compliance of arteries, the linear velocity, pulse wave velocity, compliance of vessels, peripheral vascular resistance, to assess the patency of the peripheral vessels) by the method of volumetric compression oscillometry, the analyzer parameters of blood circulation, APCO-8-the RITZ (frm «Seal», Kazan). The results and discussion. We carried out the comparison of vascular remodeling between groups of patients corresponding to the previously selected clusters. The frst cluster was considered to be prognostically more unfavorable than the second, as was characterized by higher frequency of risk factors such as advanced age, presence of diabetes mellitus and hypertension, prolonged length of coronary artery disease and arterial hypertension in the anamnesis, increased waist circumference. Conclusion. The value of the indicators of remodeling of the vascular wall (linear velocity of blood fow, peripheral vascular resistance, BP pulse) before CABG was correlated with the severity of the disease, the presence of more risk factors such as Smoking, older age, BMI, abdominal obesity; including comorbidities (diabetes, hypertension).

Key words: coronary artery bypass grafting, vascular remodeling, the risk factors of CHD, the compliance of blood vessels, pulse wave velocity, total peripheral resistance vessels, volumetric compression oscillometry.

For reference: Abzalova GF, Mayanskaya SD, Latipova ZK, Akhtereev RN. Analysis of the indicators of vascular remodeling after coronary bypass surgery depending on risk factors and comorbidities. The Bulletin of Contemporary Clinical Medicine. 2016; 9 (1): 7—12.

References

  1. Agafonov AV. Klinicheskie i strukturno–funkcional'nye osobennosti sostojanija serdca i sosudov jelasticheskogo i myshechnogo tipov, ih prognosticheskaja znachimost' u bol'nyh arterial'noj gipertenziej starshih vozrastov [Clinical and structural and functional features of the state of the heart and blood vessels elastic and muscular type, their prognostic signifcance in patients with hypertension older]. Perm' [Permian]. 2007; 47 p.
  2. Andreeva AA, Shkol'nik VV, Jarmysh NV. Vzaimosvjaz' remodelirovanija sosudov i markerov immunnogo vospalenija u pacientov s gipertonicheskoj bolezn'ju na fone abdominal'nogo ozhirenija [The relationship of vascular remodeling and immune markers of infammation in patients with hypertension on the background of abdominal obesity]. Nauchnye vedomosti Serija Medicina, Farmacija [Scientifc Gazette Series Medicine Pharmacy]. 2014; 4: 35–39.
  3. Gonchar' AV, Kovaljova ON, Hmara AT. Remodelirovanie obshhih sonnyh arterij u bol'nyh gipertonicheskoj bolezn'ju s ozhireniem [Remodeling of the common carotid arteries in hypertensive patients with obesity]. Nauchnye vedomosti Serija Medicina Farmacija [Scientific Gazette Series Medicine Pharmacy]. 2013; 18: 73–78.
  4. Cohn G, Valdes G, Capuzzi DM. Pathophysiology and treatment of the dyslipidemia of insulin resistance. Curr Cardiol Rep. 2001; 5: 416–423.
  5. Pischon T, Boeing H, Hoffmann K. General and abdominal adiposity and risk of death in Europe. N Engl J Med. 2008; 359: 2105–2120.
  6. Berger JS, Jordan CO, Lloyd–Jones D. Screening for cardiovascular risk in asymptomatic patients. J Am Coll Cardiol. 2010; 52 (12): 1169–1177.
  7. Poulos SP, Hausman DB, Hausman GJ. The development and endocrine functions of adipose tissue. Molecular and Cellular Endocrinology. 2010; 323 (1): 20–34.
  8. Oganov RG, Pogosova GV, Koltunov IE et al. Regu-ljarnoe lechenie i profilaktika — kljuch k uluch-sheniju situacii s serdechno-sosudistymi zabole-vanijami v Rossii: rezul'taty rossijskogo mnogo-centrovogo issledovanija [Regular treatment and prevention — a key to improving the situation of cardiovascular diseases in Russia: Results of a multicenter study Russian]. Kardiologija [Сardiology]. 2007; 5: 58–66.

 

PDF downloadAbout the relationship of pain, breathlessness, quality of life in patients with chronic heart failure of ischemic genesis

UDC 616.12-008.46-06

DOI: 10.20969/vskm.2016.9(1).12-17

ABROSIMOV VLADIMIR N., D. Med. Sci., professor, Head of the Department of postgraduate education of therapy with a course of family medicine of ryazan State Medical university russia, 390026, Ryazan, Vysokovoltnaya str, 9, tel. 8-910-642-13-68, e-mail: abrosimov_r@mail.ru

ZHUKOVA LYDIJA A. c. Med. Sci., associate professor of the Department of postgraduate education of therapy with a course of family medicine of ryazan State Medical university, russia, 390026, Ryazan, Vysokovoltnaya str, 9, tel. 8-910-903-81-12, e-mail: lidiyazhukova1949@yandex.ru

GLOTOV SERGEI I., c. Med. Sci., associate professor of the Department of postgraduate education of therapy with a course of family medicine of ryazan State Medical university, russia, 390026, Ryazan, Vysokovoltnaya str, 9, tel. 8-910-507-73-10, e-mail: sergeyglot@mail.ru

MELNIKOVA GALINA N  C. Med. Sci., Head of the Department of therapy of polyclinic of Ryazan regional clinical Hospital for war veterans, russia, 390000, ryazan, Voznesenskaya str, 63, tel. 8-920-633-15-43, e-mail: gv@rokgvv.issr.ru

Abstract. The aim of the present study was to assess the relationship of pain, breathlessness, quality of life in patients with chronic heart failure (CHF) of ischemic genesis. Material and methods. There were 120 patients with CHF, mean age (52,1±2,2) years, 70 of them had FC II, 39 — FC III, 11 — FC IV by NYHA classifcation. The prescription signs of CHF was 17, 5±2,2 months ago. In all patients the cause of CHF was ischemic heart disease, 100% of patients underwent one to four Q-forming myocardial infarction. Patients remained angina II-IV FC according to the classifcation of the Canadian Association of cardiologists. Physical, clinical-laboratory and instrumental methods, including ECG, Holter monitoring, ultrasound of the heart were used in this study. Psychophysiological assessment of the degree of dyspnea was performed using a visual analogue scale (VAS) and the Borg scale. Heart pain was assessed using a questionnaire Rouse. Quality of life was analyzed according to the criteria of the Minnesota questionnaire «Living with heart failure». Results and discussion. During the process of two years observations in 63 patients (52,5%) an increase of the symptoms of heart failure, primarily shortness of breath were noted, it was accompanied by slowing and sometimes the disappearance of angina attacks. In 43 patients (35,9%) the severity of heart failure and angina pectoris hadn't changed. In 14 patients (11,6%) upon increase of CHF, the frequency and the intensity of angina attacks were increased. In all the examined in the course of dynamic observation worsened the quality of life, including physical, emotional and social components. Conclusion. With the progression of CHF of ischemic genesis, the breathlessness was increased in more than half of the examined patients, the anginal syndrome was reduced or disappeared. The quality of life was suffered equally with an increase in breathlessness and increase in FC of angina.

Key words: heart failure, shortness of breath, pain, quality of life.

For reference: Abrosimov VN, Zhukova LA, Glotov SI, Melnikova GN. About the relationship of pain, breathlessness, quality of life in patients with chronic heart failure of ischemic genesis. The Bulletin of Contemporary Clinical Medicine. 2016; 9 (1): 12—17.

 

References

  1. Mareev VYu et al. Nacional'nye rekomendacii OSSN, RKO i RNMOT po diagnostike i lecheniju HSN (chetvertyj peresmotr) [National guidelines PRAs, RKO and RNMOT for diagnosis and treatment of chronic heart failure (fourth revision)]. Serdechnaja nedostatochnost' [Heart failure]. 2013; 14 (7): 379-472.
  2. Smirnova EA. Prediktory neblagoprijatnogo prognoza pri hronicheskoj serdechnoj nedostatochnosti [Predictors of a poor prognosis in patients with chronic heart failure]. Rossijskij mediko -biologicheskij vestnik imeni akademika IP Pavlova [Russian biomedical vestnik named after academician IP Pavlov]. 2011; 4: 87-91.
  3. Smirnova EA. Rasprostranennost', osobennosti diagnostiki i lechenija pacientov s hronicheskij serdechnoj nedosta-tochnost'ju [Prevalence, particularly the diagnosis and treatment of patients with chronic heart failure]. Rossijskij mediko -biologicheskij vestnik imeni akademika IP Pavlova [Russian biomedical vestnik named after academician IP Pavlov]. 2008; 1: 5-7.
  4. Filippov EV, Yakushin SS. Faktory riska serdechno — sosudistykh zabolevaniy v Ryazanskoy oblasti (po dannym issledovaniya MERIDIAN -RO) [Risk factors for cardio — vascular diseases in the Ryazan region (according to the study MERIDIAN -RO)]. Nauka molodykh (Eruditio Juvenium) [Young Science] (Eruditio Juvenium). 2013; 4: 91-105.
  5. Inoue K, Hori M. Ishemic heart failure. Nippon Rinsho. 2003; 61 (5): 862-866.
  6. Heberden W. Some account of the breast. Medical Transactions of the Royal College of Physicians of London. London. 1772; 2-59.
  7. Abrosimov VN. Odyshka [Shortness of breath]. Pul'mo-nologija: Nacional'noe rukovodstvo [Pulmonology: National leadership]. M: GEOTAR Media. 2009; 154-164.
  8. Bjalovskij JuJu. Psihologicheskie i social'nye faktory perenosimosti odyshki [Psychological and social factors portability breathlessness]. Odyshka i associirovannye sindromy: sbornik nauchnyh trudov [Shortness of breath and the associated syndromes: a collection of scientifc papers]. Rjazan'. 2005; 34-44.
  9. Dembo AG. Chto takoe odyshka? [What is shortness of breath?]. Sovetskaja medicina [Soviet medicine]. 1982; 6: 53-56.
  10. Mukharlyamov NM. Khronicheskaya nedostatochnost' kro-voobrashcheniya: rukovodstvo po kardiologii red Chazov EI [Chronic heart failure: A Guide to Cardiology, ed EI Chazov]. M: Meditsina [M: Medicine]. 1982; 3 (Bolezni serdtsa [Heart diseases]): 543-605.
  11. Abrosimov VN. Vizual'nyj analog odyshki, vozmozh-nosti prakticheskogo primenenija [Visual analogue of breathlessness, the possibility of practical application]. Terapevticheskij arhiv [Тherapeutic archives]. 1989; 3: 126-127.
  12. Borg G. Psychophysical bases of perceived exertion. Med Sci sport exerc. 1982; 14: 436-447.
  13.  Nedoshivin AO et al. Issledovanie kachestva zhizni i psihologicheskogo statusa bol'nyh s hronicheskoj serdechnoj nedostatochnost'ju [Quality of life and psychological status of patients with chronic heart failure]. Serdechnaja nedostatochnost'[Heart failure]. 2000; 1 (4): 34-37.
  14. Gendlin GE et al. Metodiki issledovanija kachestva zhizni u bol'nyh hronicheskoj serdechnoj nedostatochnost'ju [Methods of study of quality of life in patients with chronic heart failure]. Serdechnaja nedostatochnost' [Heart failure]. 2000; 1 (2): 210-212.
  15. Rector TS, Cohn JN. Assessment of Patient Outcome with the Minnesota Living with Heart failure Questionnaire: Reliability and validity during a randomized, double -blind, placebo -controlled trial of pimobendan. Am Heart J. 1992; 124: 1017-1025.
  16. Votchal BE, Magazanik NA. Sovremennye predstavlenija ob odyshke [Modern views on dyspnea]. Klinicheskaja medicina [Clinical medicine]. 1966; 3: 15-17.
  17. Breslin E et al. Perception of Fatique and quality of life in patients with COPD. Chest. 1998; 114: 958-964.
  18. Chernogorov IA. Grudnaja zhaba [Angina pectoris]. M: Medgiz. 1954; 93 p.
  19. Banzett RB, Moosavi ShH. Dyspnea and Pain: Similarities and Contrasts Between Two Very Unpleasant Sensations. APS Bulletin. 2001; 11(2): 678-680.
  20. Frankshtejn SI. Dyhatel'nye refeksy i mehanizmy odyshki [Respiratory reflexes and mechanisms of dyspnea]. M: Medicine; 205 p.
  21. Rose GA, Blackburn H. Cardiovascular survey methods: monog ser WHO. Geneva: WHO. 1968; 56: 316-318.

 

PDF downloadAnalysis of medical representatives' activities directed to physicians in Egypt 

UDC 615.1:339.13(620)

DOI: 10.20969/vskm.2016.9(1).17-23

BAHLOL MOHAMMED MOSTAFA HOSSNI ABDELAZIZ, graduate student of the Departament of management and economics of pharmacy, medical faculty, russian People’s friendship university, russia, 117198, Moscow, Mikluho-Maklaj str, 21, build. 1, e-mail: Ph_hossni@yahoo.com, citizenship: Egypt

LAGUTKINA TATIANA P., D. Pharm. Sci., professor of the Department of management and economics of pharmacy, medical faculty, russian People’s friendship university, russia, 117513, Moscow, leninski av, 135-1-591, e-mail: lagutkina.t@gmail.com, citizenship: Russia

Abstract. Aim. This paper aims to investigate medical representatives' (a form of personal selling) activities directed to physicians in Egyptian pharmaceutical market. Materials and methods. Surveying through simple random probability sampling is the approach appropriate for broad and representative overview of situation in research. Therefore, a survey of 1068 physicians was conducted through interviews and establishing structured data collection questionnaire. Results and discussion. This is the frst empirical paper to investigate medical representatives' activities directed to physicians in Egyptian pharmaceutical market. These activities include identifying of medical representatives’ activities through analysis of their visits, type of information introduced by medical representatives to physicians, using of free samples by medical representatives and compliance to ethical criteria, the required personal qualities and educational level of medical representatives as seen by physicians. These fndings are useful for managers in pharmaceutical industry. They can be also useful in other industries such as medical equipment. Conclusion. Pharmaceutical companies are widely employing medical representatives, as the most effective and widely-applied technique in Egypt, but they don't sometimes comply to pharmaceutical promotion ethical criteria. Aligning marketing management vision with market real situation will lead to synergism effect in employing medical representatives.

Key words: medical representatives, physicians, pharmaceutical market, Egypt.

For reference: Bahlol MM, Lagutkina TP Analysis of medical representatives' activities directed to physicians in egypt. The Bulletin of Contemporary Clinical Medicine. 2016; 9 (1): 17—23.

 

References

  1. Lagutkina T, Bahlol M. Izuchenie organizacionnyh aspektov prodvizhenija na farmacevticheskom rynke egipta [Survey on using marketing promotion by pharmaceutical producers in Egypt]. Mezhdunarodnyj nauchno-issledovatel'skij zhurnal [International research journal], 2015; 4-3 (35): 48-52.
  2. Dixon AL, Spiro RL, Jamil M. Successful and unsuccessful sales calls: Measuring salesperson attributions and behavioral intentions. Journal of Marketing. 2001; 65 (3): 64-78.
  3. Kotler P. Marketing management: A south Asian perspective: Pearson Education India; 2009 [cited 26 Jan 2016]. Available from: http://www.abebooks.com/servlet/ BookDetailsPL?bi=13954160626&searchurl=isbn%3D9 788131716830.
  4. Jackson DW, Cunningham WH, Cunningham IC. Selling: The personal force in marketing: John Wiley & Sons; 1988 [cited 26 Jan 2016]. Available from: http://www. amazon.com/Selling-Marketing-William-J-E-Crissy/ dp/0471637661.
  5. Gomez-Mejia LR, Balkin DB, Cardy RL. Managing human resources: Prentice Hall Upper Saddle River; 2004 [cited
    26 Jan 2016]. Available from: https://www.google.com.eg/ url?sa=t&rct=j&q=&esrc=s&source=web&cd=4&cad=rja& uact=8&ved=0ahUKEwjdwpK_qsfKAhXD83IKHaFbAuQQ FggmMAM&url=http%3A%2F%2Fwww.tuyiau.ac.ir%2Ffa %2Fcomponent%2Fattachments%2Fdownload%2F115& usg=AFQjCNGmvUnjxf-OTdKmVzRGqD4H4VooA&bvm =bv.112766941,d.bGQ.
  6. Krafft M. An empirical investigation of the antecedents of sales force control systems. The Journal of Marketing. 1999; 1: 120-134.
  7. Chu W, Gerstner E, Hess JD. Costs and benefits of hard-sell. Journal of Marketing Research. 1995; 1: 97-102.
  8. Mantrala MK, Sinha P, Zoltners AA. Structuring a multiproduct sales quota-bonus plan for a heterogeneous sales force: A practical model-based approach. Marketing Science. 1994; 13 (2): 121-144.
  9. Chowdhury J. The motivational impact of sales quotas on effort. Journal of Marketing Research. 1993 [cited 26 Jan 2016]. Available from: http://search.proquest. com/openview/af116092ada9c9c81f717f9fa34f1d09/1 ?pq-origsite=gscholar.
  10. Churchill GA, Ford NM, Walker OC, Johnston MW, Tanner JF. Sales force management: Irwin/McGraw-Hill Boston, MA; 2005[cited 26 Jan 2016]. Available from: http://www. amazon.com/Churchill-Walkers-Management-Mcgraw-Hill-Marketing/dp/007296183X.
  11. Kotler P, Rackham N, Krishnaswamy S. Ending the war between sales and marketing. Harvard Business Review. 2006; 84 (7/8): 68.
  12. Smith TM, Gopalakrishna S, Chatterjee R. A three-stage model of integrated marketing communications at the marketing-sales interface. Journal of Marketing Research. 2006; 43 (4): 564-579.
  13. Fisher C. Researching and writing a dissertation: a guidebook for business students: Pearson Education; 2007[cited 26 Jan 2016]. Available from: http://www.amazon.co.uk/ Researching-Writing-Dissertation-Guidebook-Business/ dp/0273710079.
  14. Bardelay D, Bécel D. Visits from medical representatives: Fine principles, poor practice. Prescrire International. 1995; 4 (18): 120-122.
  15. Code of Marketing Practices of the Association of International Pharmaceutical Manufacturers [cited 26 Jan 2016]. Available from: http://www.ifpma.org/fleadmin/ content/About%20us/2%20Members/Associations/Code-Russia/1_RUS-EN-Code-2009[1].pdf.
  16. Code of the International Federation of Pharmaceutical Manufacturers Associations [cited 26 Jan 2016]. Available from: http://www.ifpma.org/fleadmin/content/ Publication/2012/IFPMA_Code_of_Practice_2012_new_ logo.pdf.
  17. Usenko V, Spasokukockij A. Licenzirovanie v Evropejskom sojuze: farmacevticheskij sektor [Licensing in the European Union: the pharmaceutical sector]. K: Morion [K: Morion]. 1998; 61-66 p.
  18. Ethical WHO (21 Assembly of WHO, 1968, Resolution 21/41; 39 Assambel of WHO, 1986, Resolution 39/27; 47 Assembly of WHO, 1994, Report of the CEO of A47/7) [cited 26 Jan 2016]. Available from:http://apps.who.int/iris/ bitstream/10665/177057/1/WHA47_A-Conf.Paper-2_eng. pdf.
  19. Egyptian law of practicing pharmacy profession No 127/1955 [cited 26 Jan 2016]. Available from: http://pcm. me/ph-practice-law-in-egypt.

 

PDF downloadRespiratory diseases in Tatarstan: perennial epidemiological analysis

УДК 616.2-036.22(470.41)“1994/2014”

DOI: 10.20969/vskm.2016.9(1).24-31

VAFIN ADEL YU., c. Med. Sci., associate professor, Head of the Department of health management medical of Kazan State Medical university, Minister of Health of the republic of Tatarstan, tel. 8-987-231-79-98, e-mail: minzdrav@tatar.ru

VIZEL ALEXANDER A., D. Med. Sci., professor, Head of the Department of phthisiopulmonology of Kazan State Medical university, chief freelance specialist pulmonologist Ministry of Health of Tatarstan, Russia, Kazan, tel. +7-987-296-25-99, e-mail: lordara@inbox.ru

SHERPUTOVSKY VLADIMIR G., c. Med. Sci., director of the republican medical analysis centre of Ministry of Health of the republic of Tatarstan, Russia, Kazan, tel. +7-843-221-16-50, e-mail: mz.rmiac@tatar.ru

LYSENKO GALINA V., c. Med. Sci., Head of Government of the control standards and the quality of medical activity of the Ministry of Health of the republic of Tatarstan, tel. +7-843-231-79-73, e-mail: Galina.lysenko@tatar.ru

KOLGIN ROMAN A., Head of the Department of medical statistics, Director of republican medical analytical center of Ministry of Health of the republic of Tatarstan, tel. +7-843-221-16-50, e-mail: Kolgin.roman@tatar.ru

VIZEL IRINA YU., c. Med. Sci., assistant of professor of the Department of phthisiopulmonology of Kazan State Medical University, Tussia, Kazan, tel. +7-903-388-71-64, e-mail: tatpulmo@mail.ru

SHAYMURATOV RUSTEM I., postgraduate student of the Department of phthisiopulmonology of Kazan State Medical University, Russia, Kazan, tel. +7-917-900-55-10, e-mail: russtem@gmail.com

AMIROV NAIL B., D. Med. Sci., professor of the Department of general practice of Kazan State Medical university, Russia, Kazan, tel. +7-905-313-01-11, e-mail: namirov@mail.ru

Abstract. Aim. To analyze main epidemiological data of respiratory diseases in Tatarstan Republic from 1994 to 2014. Material and methods. Data on the incidence and prevalence was obtained from Republican Medical Analytical Center of Ministry of Health of Tatarstan. We compared these data with Tatarstanstat, Rosstat and basic demographics. Incidence and prevalence are given per 100 thousand population. Results. The incidence and prevalence of respiratory infections in Tatarstan for the past 20 years gradually increased. Mortality from respiratory infections decreased from 71,0 to 46,8 (-34%), and the mortality rate increased from 0,41% to 0,51% (+24,3%). The increased incidence of CAP in 2014 was 18,8%. However, over the last three years the incidence of CAP decreased to 22,4%. From 1995 to 2005, mortality increased, but by 2014 it had reduced to 21,2 (-14,9%). The mortality rate in 2014 dropped to 2,1%. The incidence of asthma has reached a peak in 2007, declined in the last 6 years and reached 71,3. The prevalence of asthma has increased over the 20 years to 895,4 (+184,4%). Mortality from asthma has decreased from 11,8 to 2,19 (-81,4%) and the mortality rate from 0,59% to 0,18% (-69,4%). The increase (+270,7%) of the incidence of COPD was registered from 1994 to 2012 and from 2012 to 2014 it decreased to 20,1%. The prevalence of COPD in 20 years increased by 28,4%. By 2014, the mortality rate reduced to 21,2 (-41,2%). Mortality 20 years declined by 66,8%. Conclusion. The analysis identifed three major trends — increased incidence and prevalence, mortality reduction and stabilization of the mortality fgures in the background of a signifcant reduction in the duration of hospital stay. Such dynamics are generally characterized by the epidemiological situation as favorable.

Key words: respiratory diseases, prevalence, morbidity, mortality, epidemiology.

For reference: Vafn AYu, Vizel AA, Sherputovsky VG, Lysenko GV, Kolgin RA, Vizel IYu, Shaymuratov RI, Amirov NB. Respiratory diseases in tatarstan: perennial epidemiological analysis. The Bulletin of Contemporary Clinical Medicine. 2016; 9 (1): 24—31.

References

  1. URL: http://www.who.int/mediacentre/factsheets/fs310/ en/index.html
  2. Welte T. Respiratory epidemiology: ERS monograph Ed. European Respiratory Society. 2014; 62–78, 116–124.
  3. Chuchalin AG, Avdeev SN, Ajsanov ZR i dr. Rossijskoe respiratornoe obshhestvo: Federal'nye klinicheskie rekomendacii po diagnostike i lecheniju hronicheskoj obstruktivnoj bolezni legkih [Russian Respiratory Society: Federal clinical guidelines on diagnostic and treatement of Chronic Obstructive Pulmonary Disease]. Pul'monologija [Pulmonology]. 2014; 3: 15–36.
  4. Obshhaja zabolevaemost' vsego naselenija Rossii v 2012 godu: Statisticheskie materialy, chast' II, Ministerstvo zdravoohranenija Rossijskoj Federacii, departament analiza, prognoza i innovacionnogo razvitija zdravoohranenija FGBU «Central'nyj nauchno–issledovatel'skij institut organizacii i informatizacii zdravoohranenija» Minzdrava [The overall incidence of the entire population of Russia in 2012: Statistical data, part II, The Ministry of Health of the Russian Federation, department of analysis, forecasting and innovative health development FGBI «Central Research Institute for Public Health» Ministry of Health]. Moskva [Moscow]. 2013; 140 p.
  5. Bedilo NV, Vorob'eva NA, Ismajlova NV, Veshhagina NA. Jepidemiologija vnebol'nichnyh pnevmonij v gorode Arhangel'ske [Epidemiology of community acquired pneumonia in Arkhangel'sk city]. Jekologija cheloveka [Human Ecology]. 2013; 8: 45–51.
  6. Kolosov VP, Kurganova OP et al. Jepidemiologicheskie osobennosti vnebol'nichnyh pnevmonij v Amurskoj oblasti, problemy i puti reshenija [Epidemiological features of community–acquired pneumonia in the Amur region, problems and solutions]. Bjulleten' fziologii i patologii dyhanija [Respiratory physiology bulletin]. 2014; 53; 10–17.
  7. Bljumental' IJa. Vnebol'nichnaja pnevmonija: aktual'naja problema ili rutinnaja patologija? [Community–acquired pneumonia: actual problem or routine pathology?]. Vestnik sovremennoj klinicheskoj mediciny [Bulletin of Contemporary Clinical Medicine]. 2011; 1; 52–55.
  8. Rozenbaum MH, Mangen MJ, Huijts SM, van der Werf TS, Postma MJ. Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: A nationwide retrospective claims database analysis. Vaccine. 2015; 33 (28): 3193–3199.
  9. Corsi DJ, Boyle MH, Lear SA, Chow CK, Teo KK, Subramanian SV. Trends in smoking in Canada from 1950 to 2011: progression of the tobacco epidemic according to socioeconomic status and geography. Cancer Causes Control. 2014; 25 (1): 45–57.
  10. Hanin AL, Chernushenko TI. Problemy boleznej organov dyhanija i vozmozhnye puti ih reshenija na urovne municipal'nogo zdravoohranenija [Problems of respiratory diseases and their possible solutions on municipal health care level]. Pul'monologija [Pulmonology]. 2011; 2: 115–118.
  11. Vizel AA, Vizel IJu, Amirov NB. Hronicheskaya obstructivnaya bolezn' ljogkih. Peremeny kak povod dlja obsuzhdeniaj [Chonic obstructive pulmonary disease (COPD). Changes as acauce for discussion]. Vestnik sovremennoi klinicheskoi mediciny [The Bulletin of Contemporary Clinical Medicine]. 2015; 8(1): 62–69.

 

 

PDF downloadAssociation of oxidative metabolism phenotype and clinical efficacy of proton pump inhibitors in patients with gastroesophageal reflux disease 

UDC [616.329-002-02:616.33-008.17]-085.243.4

DOI: 10.20969/vskm.2016.9(1).31-36

KALUGIN ANDREY A., full-time postgraduate student of the Department of internal diseases of the postgraduate education faculty of Kursk State Medical university, russia, 305041, Kursk, Karl Marx str., 3, tel. +7-951-338-77-27, e-mail: dr.kalugin2010@yandex.ru

STEPCHENKO ALEKSANDER A., professor of the Department of internal diseases of the postgraduate education faculty of Kursk State Medical university, russia, 305041, Kursk, Karl Marx str., 3, tel. 7-910-210-83-50, e-mail: therapy-fpo@mail.ru

Abstract. Aim. Research of the clinical effcacy of proton pump inhibitors in patients with gastroesophageal refux disease (GERD) with various phenotypes of oxidative metabolism, detected using the marker drug aminophylline. Material and methods. 65 patients were included into the study. Oxidative metabolism phenotype was evaluated by the aminophylline half-elimination period (method of aminophylline salivary detection was used), and the phenotype groups were classifed into «quick», «slow» and «very slow» metabolizers. Helicobacter pylori was diagnosed using the urease breath test. Clinical effcacy of the standard omeprazole dose (20 mg OD) was evaluated by relieving heartburn and pain syndrome. Results and discussion. The conducted research revealed that among 65 patients with GERD quick oxidation phenotype was detected in 32,3% of patients, and slow oxidation phenotype — in 49,2% of patients, while in 18,5% of patients very slow oxidation phenotype was detected. When evaluating the impact of treatment on GERD clinical signs, quicker relief of heartburn was noted in the subgroup of very slow metabolizers compared to quick metabolizers. When comparing quick and slow metabolizers, the frequency of Helicobacter pylori eradication was signifcantly lower in the subgroup of quick metabolizers as opposed to very slow ones. Conclusion. Assessment of the rate of drug oxidative metabolism in liver enables the individualization of omeprazole treatment in patients with GERD. Apparently, in quick oxidation phenotype it is necessary to increase the daily dose of omeprazole. Patients with GERD and slow oxidation phenotype should be expected to have signifcant short-term clinical effect of standard omeprazole doses. Eradication therapy with the standard doses of drugs was less effective both in clinical and economic terms in patients with GERD and quick oxidative metabolism phenotype, unlike slow and very slow metabolizers.

Key words: gastroesophageal refux disease, omeprazole, oxidative metabolism phenotype, Helicobacter pylori.

For reference: Kalugin AA, Stepchenko AA. Association of oxidative metabolism phenotype and clinical effcacy of proton pump inhibitors in patients with gastroesophageal refux disease. The Bulletin of Contemporary Clinical Medicine. 2016; 9 (1): 31—36.

 

References

  1. Ivashkin VT, Lapina TL. Gastrojenterologija: nacional'noe rukovodstvo: kratkoe izdanie [Gastroenterology: national Leadership: short edition]. M: GJeOTAR–Media. 2011: 404–411.
  2. Maev IV, Andreev DN, Dicheva DT. Gastrojezofageal'naja refjuksnaja bolezn': ot patogeneza k terapevticheskim aspektam [Gastroesophageal reflux disease: from pathogenesis to therapeutic aspects]. Consilium–medicum. 2013; 15 (8): 30–34.
  3. Ivashkin VT. Racional'naja farmakoterapija zabolevanij organov pishhevarenija: Rukovodstvo dlja prakticheskih vrachej [Rational pharmacotherapy of diseases of the digestive system: a guide for practitioners]. M: ZAO «Izdatel'stvo Littera». 2007; 310–324.
  4. Sheptulin AA. Covremennye vozmozhnosti i perspektivy lechenija rezistentnyh form gastrojezofageal'noj refjuksnoj bolezni [Modern opportunities and prospects for treatment of resistant forms of gastroesophageal refux disease]. Rossijskij zhurnal gastrojenterologii, gepatologii i koloproktologii [The Russian Journal of gastroenterology, hepatology, coloproctology]. 2010; 6: 81–85.
  5. Maev IV, Samsonov AA, Andreev NG, Beljavceva EV. Dlitel'naja, kombinirovannaja terapija GJeRB — put' k podderzhaniju dolzhnogo kachestva zhizni i garantija ot oslozhnennogo techenija zaboleva-nija [Continuous, combined therapy of GERD — a way to maintain good quality of life and a guarantee from complications of the disease]. Klinicheskie perspektivy gastrojenterologii, gepatologii [Clinical prospects of gastroenterology, hepatology]. 2011; 2: 11–17.
  6. Skorjatina IA, Kutafna NV. Agregacionnye vozmozhnosti trombocitov pri arterial'noj gipertonii i dislipidemii na fone atorvastatina i nemedikamentoznogo vozdejstvija [Aggregating the possibility of platelets in arterial hypertension and dyslipidemia in the background of atorvastatin and non–drug exposure]. Vestnik Surgutskogo gosudarstvennogo pedagogicheskogo universiteta [Bulletin of the Surgut State Pedagogical University]. 2015; 1 (34): 258–265.
  7. Rapoport SI. Gastrojezofageal'naja refjuksnaja bolezn' (Posobie dlja vrachej). [Gastroesophageal refux disease (Manual for Physicians)]. M: ID «MEDPRAKTIKA–M». 2009; 12 p.
  8. Malfertheiner P, Megraud F, O`Morain C, Atherton J, Axon A, Bazzoli F, Gensini GF, Gisbert J, Graham D, Rokkas T, El–Omar E, Kuipers E. Management of Helicobacter Pyloriinfection — Maastricht IV; Florence Consensus Report. 2012; 61: 646–664.
  9. Kukes VG. Klinicheskaja farmakokinetika [Klinicheskaja farmakokinetika]. M: GJeOTAR–Media. 2009; 432 p.
  10. Kukes VG, Grachev SV, Sychev DA, Ramenskaja GV. Metabolizm lekarstvennyh sredstv: nauchnye osnovy personalizirovannoj mediciny: ruk dlja vrachej [Metabolism of drugs: scientifc basis for personalized medicine: a guide for doctors]. M: GJeOTAR–Media. 2008; 304 p.
  11. Kachmarskaja LM. Izuchenie individual'noj variabel'nosti biotransformacii teofllina [Studying individual variability biotransformation of theophylline]. Aktual'nye voprosy jekstrennoj specializirovannoj medicinskoj pomoshhi [Topical issues of urgent specialized medical care]. Orel. 1996; 246–247.
  12. Kachmarskaja LM. Opredelenie teofillina v sljune [Determination of theophylline in saliva]. Aktual'nye voprosy jekstrennoj specializirovannoj medicinskoj pomoshhi [Topical issues of urgent specialized medical care]. Orel. 1996: 51–53.
  13. Mishhenko EV, Filippenko NG, Povetkin SV. Farmako-jekonomicheskoe obosnovanie primenenija omeprazola pri jazvennoj bolezni [Pharmacoeconomic rationale for the use of omeprazole in ulcer disease]. Kurskij nauchno– prakticheskij vestnik «Chelovek i ego zdorov'e» [Kursk Scientifc and Practical Bulletin “Man and His Health”]. 2003; 4: 65–68.
  14. European Helicobacter Pylori Study Group. Current European concepts in the management of Helicobacter pylori infection: the Maastricht Consensus Report. 1997; 41: 8–13.
  15. Amelina IV, Medvedev IN. Vzaimosvjaz' aktivnosti jadryshkoobrazujushhih rajonov hromosom i somato-metricheskih pokazatelej u cheloveka [The relationship of activity of nucleolar organizer regions of chromosomes and somatometric indicators in humans]. Bjulleten' jeksperimental'noj biologii i mediciny [Bulletin of Experimental Biology and Medicine]. 2009; 147 (1): 82–85.

 

 

PDF downloadEfficacy evaluation of acetylation phenotype as a criterion for predicting the course and outcome of a burn injure to the eyes 

UDC 617.7-001.17-036

DOI: 10.20969/vskm.2016.9(1).36-40

KAMILOV KHALIDZHAN M., D. Med. Sci., professor, Head of the Department of ophthalmology of tashkent institute of Postgraduate Medical education, Hero of Uzbekistan, Uzbekistan, 100055, Tashkent, Shaikhantakhur district, General Uzakov str., 59, tel. +9-98-93-595-00-55

MAKSUDOVA LAYLO M., assistant of professor of the Department of ophthalmology of tashkent institute of Postgraduate Medical education, uzbekistan, 100194, tashkent, Yunus-Abad district, block 3, house 3, tel. +9-98-93-595-00-55, +9-98-71-221-83-40, e-mail: doclaylo@rambler.ru, doclaylo@gmail.com

Abstract. Aim. The study was performed on 103 patients with chemical burns of the eyes, of which 52 patients with slow (SAPh) and 51 patients with fast acetylation phenotype (FAPh). The patient examination included general ophthalmological and special methods of study. Material and methods. All patients in the dynamics (of 2, 5, 7, 12, 30 days and 4 months after burns) were performed immunocytochemical studies with identifcation of antigen-binding lymphocytes (ABLs) indicators, specifcally sensitized to the tissue-specifc antigens (TSAs) of anterior segment of the eye tissues: cornea , sclera, lens and choroid. Results and discussion. It was found that acetylation phenotype determines the nature and duration of the risk of development and progression of complications during chemical eye burns. Fast acetylation phenotype may serve as a predictor of susceptibility to a more rapid regression of pathological changes in the tissues of the anterior segment of the eye, SAPh predisposes to more severe forms with protracted process. Conclusion. Determination of the APh as well as the study of the dynamics of the disease ABLs indicators, specifcally sensitized to the corresponding TSAs may be prognostic markers of various outcomes of the pathological process and the effectiveness of the treatment.

Key words: acetylation phenotype (APh), antigen-binding lymphocytes (ABLs), risk of development and progression of complications, destructive eye disorders, eye burns, predicting clinical outcomes.

For reference: Kamilov HM, Maksudova LM. Effcacy evaluation of acetylation phenotype as a criterion for predicting the course and outcome of a burn injure to the eyes. The Bulletin of Contemporary Clinical Medicine. 2016; 9 (1): 36—40.

 

References

  1. Garib FJu, Gurarij NI, Afanas'ev JuI et al. Klinicheskaja cennost' opredelenija antigensvjazyvajushhih kletok u bol'nyh brjushnym tifom i drugimi zabolevanijami: metodicheskie rekomendacii [Clinical value of determination of antigen–binding cells in patients with typhoid fever and other diseases: guidelines]. Tashkent. 1983; 40 p.
  2. Guljamov NG, Ahmedova HJu, Dalimov TK, Imamova IA, Juldasheva FZ. Diagnosticheskoe znachenie pokazatelej antigensvjazyvajushhih limfocitov v ocenke porazhenija organov pri infekcionnoj i neinfekcionnoj patologii [Diagnostic value of lymphocyte antigen in the assessment of organ damage in infectious and noninfectious diseases]. Infekcija, immunitet i farmakologija [Infection, immunity and pharmacology]. 2005; 3: 115–118.
  3. Guljamov NG, Ahmedova HJu, Igamberdieva SD. Immunologicheskaja diagnostika organopatologii pri brucelleze: metodicheskie rekomendacii [Immunological diagnosis of brucellosis in the organopathology: guidelines]. Tashkent. 2012; 20 p.

 

 

PDF downloadStandardization and adaptation review in phar-maceutical marketing promotions

УДК 615.1:339.138(100)

DOI: 10.20969/vskm.2016.9(1).40-45

LAGUTKINA TATIANA P., D. Pharm. Sci., professor of the Department of management and economics of pharmacy, medical faculty, russian People’s friendship university, russia, 117513, Moscow, leninski av, 135-1-591, e-mail: lagutkina.t@gmail.com, citizenship: Russia

BAHLOL MOHAMMED MOSTAFA HOSSNI ABDELAZIZ, graduate student of the Departament of management and economics of pharmacy, medical faculty, russian People’s friendship university, russia, 117198, Moscow, Mikluho-Maklaj str, 21, build. 1, e-mail: Ph_hossni@yahoo.com, citizenship: Egypt

Abstract. Aim. International business has dramatically been expanding. Pharmaceutical companies expanded in foreign markets in order to survive. Importance of international marketing strategy has been rising due to increase of foreign market percentage from total world market and foreign competition. Accordingly, pharmaceutical companies marketing strategy should be coordinated in different countries. Material and methods. Reviewing of an immense argumentation with regard to appropriate marketing strategy in different markets of different countries. Results and discussion. There are two marketing strategy choices, i.e., either standardization or adaptation. There are both advantages and disadvantages of standardization and adaptation in pharmaceutical marketing promotion. Conclusion. There are a lot of factors affecting standardization and adaptation. These factors are related to the product, the hosting market and the pharmaceutical company itself. Mixing both standardization and adaptation in marketing strategy of pharmaceutical companies should be done in a real life practice. Pharmaceutical companies should aggregate the worldwide heterogeneous market into homogenous clusters. These aggregations depend on similarities of attitude to demand or offers between countries in each cluster and can be done at cross cultural or geographical level.

Key words: standardization, adaptation, factor, marketing strategy, pharmaceutical company.

For reference: Lagutkina TP, Bahlol MM. Standardization and adaptation review in pharmaceutical marketing promotions. The Bulletin of Contemporary Clinical Medicine. 2016; 9 (1): 40—45.

 

References

  1. Levitt T. The globalization of markets. Harvard Business Review. 1983; 61(3): 69–81.
  2. Boddewyn JJ, Soehl R, Picard J. Standardization in international marketing: isTed Levitt in fact right? Business Horizon. 1986; 29 (6): 69–75.
  3. Melewar T, Vemmervik C. International advertising strategy: A review, reassessment and recommendation. Management Decision. 2004; 42 (7): 863–881.
  4. Agrawal M. Review of a 40–year debate in international advertising: Practitioner and academician perspectives to the standardization/adaptation issue. International Marketing Review. 1995; 12 (1): 26–48.
  5. Scholte JA. What is globalization? The defnitional issue– again. CSGR Working Paper. 2002; 109 / 02: 48 р.
  6. Globalization. In Merriam–Webster Online Dictionary. 2010; Available from: http://www.merriam–webster.com/ dictionary/globalization.
  7. Kotler P. Global standardization—courting danger. Journal of Consumer Marketing. 1986; 3 (2): 13–15.
  8. Frankel JA. Measuring international capital mobility: a review. The American Economic Review. 1992: 197–202.
  9. Feenstra RC. Integration of trade and disintegration of production in the global economy. The journal of economic perspectives. 1998; 12 (4): 31–50.
  10. Richen A, Steinhorst A. Standardization or harmonization? you need both. European Health Informatics. 2005; 5: Available from: www. bPTrends.com.
  11. Obstfeld M, Taylor AM. Global capital markets: integration, crisis, and growth. New York: Cambridge University Press. 2004; 354 p.
  12. Theodosiou M, Leonidou LC. Standardization versus adaptation of international marketing strategy: an integrative assessment of the empirical research. International Business Review. 2003; 12 (2): 141–171.
  13. Papavassiliou N, Stathakopoulos V. Standardization versus adaptation of international advertising strategies: towards a framework. European Journal of Marketing. 1997; 31 (7): 504–527.
  14. Samiee S, Roth K. The infuence of global marketing standardization on performance. The Journal of Marketing. 1992; 56 (2): 1–17.
  15. Douglas SP, Wind Y. The myth of globalization. Columbia Journal of World Business. 1987; 22 (4): 19–29.
  16. Szymanski DM, Bharadwaj SG, Varadarajan PR. Standardization versus adaptation of international marketing strategy: an empirical investigation. The Journal of Marketing. 1993; 57 (4): 1–17.
  17. Medina JF, Duffy MF. Standardization vs globalization: a new perspective of brand strategies. Journal of Product & Brand Management. 1998; 7 (3): 223–243.
  18. Kuvykaitė R, Alimienė M. Standardization/adaptation of marketing solutions in companies operating in foreign markets: An integrated approach. Engineering economics. 2008; 1 (56): 37–47.
  19. Pratt EE. Modern international commerce: Allyn and Bacon. Journal of Marketing. 1957; 21 (4): 492–494.
  20. Wang X, Yang Z. Standardization or adaptation in international advertising strategies: The roles of brand personality and country–of–origin image. Asian Journal of Business Research. 2011; 1 (2): 25–36.
  21. Marshall SW, Roberts MS. International Advertising Strategy. The Handbook of International Advertising Research. 2014; 21: 251–269.
  22. Buzzell RD. Can you standardize multinational marketing? Reprint Service. Harvard business review; 1968; 49: 102–113.
  23. Ryans JK. Is it too soon to put a tiger in every tank. Columbia Journal of World Business. 1969; 4 (2): 69–75.
  24. Miracle GE. International advertising principles and strategies. MSU Business Topics. 1968; 16 (3): 29–36.
  25. Smith WR. Product differentiation and market segmentation as alternative marketing strategies. The Journal of Marketing. 1956; 21 (1): 3–8.
  26. Dickson PR, Ginter JL. Market segmentation, product differentiation, and marketing strategy. The Journal of Marketing. 1987; 51: 1–10.
  27. Solberg CA. Standardization or adaptation of the international marketing mix: the role of the local subsidiary/ representative. Journal of International Marketing. 2000; 8 (1): 78–98.
  28. Zou S, Cavusgil ST. The GMS: a broad conceptualization of global marketing strategy and its effect on frm performance. Journal of Marketing. 2002; 66 (4): 40–56.
  29. Toyne B, Walters PGP. Global Marketing Management: A Strategic Perspective, 1st Ed. Boston: Allyn and Bacon. 1988; 747 p.
  30. Mooij MK, Keegan WJ. Advertising worldwide, Concepts, theories and practice of international, multinational and global advertising. Hertfordshire: Prentice Hall. 1991; 440 p.
  31. Mülbacher H, Dahringer L, Leihs H. International Marketing: A Global Perspective. Cengage Learning Business Press. 1999; 768 p.

 

 

PDF downloadStudy of the efficacy, safety and tolerability of the combined use of glucosamine sulfate («artrakam») and chondroitin sulfate («artradol») in patients with osteoarthritis of the knee 

UDC 616.728.3-085.27

DOI: 10.20969/vskm.2016.9(1).45-51

LAPSHINA SVETLANA A., c. Med. Sci., associate professor of the Department of hospital therapy of Kazan State Medical University, research worker of the Department scientific of republican clinical hospital, Russia, Kazan, e-mail: svetlanalapshina@mail.ru

AFANASIEVА MARIANNА A., physician of the Department of rheumatology of republican clinical hospital, Russia, Kazan

SUKHORUKOVA ELENA V., physician of the Department of rheumatology of republican clinical hospital, Russia, Kazan

AKHTYAMOV ILDAR F., D. Med. Sci., professor, Head of the Department of traumatology, orthopedics and surgery in extreme conditions of Kazan State Medical University, research worker of the Department of republican clinical hospital, Russia, Kazan, e-mail: yalta60@mail.ru

MYASOUTOVA LEYSAN I., assistant of the professor of the Department of hospital therapy of Kazan State Medical University, Russia, Kazan

Abstract. Аim. Assessment the effcacy and safety of combined use of drugs «Artradol» (chondroitin sulfate) and «Artrakam» (glucosamine sulfate) in patients with osteoarthritis (OA) of the knee. Material and methods. We examined 30 patients with a diagnosis of OA of knee joints and severe pain, mean age of (58,7±5,1) years; mean duration of disease was (5,9±2,9) years. Patients were administered preparations of chondroitin sulfate («Artradol») and intramuscular glucosamine sulfate («Artrakam») alternating every other day for 2 months. Effcacy of therapy was determined after 1 and 2 months of treatment for dynamics of indices: the pain intensity in the joint (VAS), the circumference of the joint, the WOMAC index, the need for NSAIDs, the effectiveness of the therapy according to the patient and the doctor. Results. After 2 months of therapy with preparations of glucosamine and chondroitin sulfate there was a signifcant (p<0,05) reduction of pain during movement, tenderness of joints on palpation, circumference of knee joint, reduction of the WOMAC index, the time of passing the distance of 15 meters, need to NSAIDs, relief of local infammation in the joints. Effcacy of therapy was assessed by patients and doctors as good and satisfactory. Serious side effects have been reported. Conclusion. Combination therapy drugs «Artradol» and «Artrakam» is effective in the treatment of knee OA.

Key words: knee osteoarthritis; glucosamine sulfate; chondroitin sulfate.

For reference: Lapshina SA, Afanasievа MA, Sukhorukova EV, Akhtyamov IF, Myasoutova LI. Study of the effcacy, safety and tolerability of the combined use of glucosamine sulfate («Аrtrakam») and chondroitin sulfate («Аrtradol») in patients with osteoarthritis of the knee. The Bulletin of Contemporary Clinical Medicine. 2016; 9 (1): 45—51.

 

References

  1. Nasonova EL. Revmatologija: klinicheskie rekomendacii. [Rheumatology: clinical guidelines]. M: GJeOTAR–Media [GEOTAR Media]. 2010; 752 p.
  2. Turovskaja EF, Alekseeva LI, Filatova EG. Sovremennye predstavlenija o patogeneticheskih mehanizmah boli pri osteoartroze. Nauchno–praktich revmatol [Scientifc and Practical Revmatol]. 2014; 52 (4): 438–444.
  3. Folomeeva OM, Lobareva LS, Ushakova MA. Invalidnost', obuslovlennaja revmaticheskimi zabolevanijami, sredi zhitelej Rossijskoj Federacii [The disability caused by rheumatic diseases among the inhabitants of the Russian Federation]. Nauchno–praktich revmatol [Scientifc and Practical revmatol]. 2001; 1: 15–21.
  4. Neogi T. The epidemiology and impact of pain in osteoarthritis. Osteoarthritis Cartilage. 2013; 21 (9): 1145‒1153.
  5. Lee YC, Nassikas N, Clauw DJ. The role of the central nervous system in the generation and maintenance of chronic pain in rheumatoid arthritis, osteoarthritis and fbromyalgia. 2011; 13 (2): 211.
  6. Ayis S, Dieppe P. The natural history of disability and its determinants in adults with lower limb musculoskeletal pain. J Rheumatol. 2009; 36: 583‒591.
  7. Dominick KL, Ahern FM, Gold CH, Heller DA. Health– related quality of life and health service use among older adults with osteoarthritis. Arth Rheum. 2004; 51: 326‒331.
  8. Loeser R, Goldring S, Scanzello C, Goldring M. Osteoarthritis; a Disease of the Joint as an Organ. Arthr Rheum. 2012; 64 (6): 1697‒1707.
  9. Goldring MB, Marcu KB. Cartilage homeostasis in health and rheumatic diseases. Arth Res Ther. 2009; 11: 224.
  10. Pulai JI, Chen H, Im HJ. NF–κB mediates the stimulation of cytokine and chemokine expression by human articular chondrocytes in response to ibronectin fragments. J Immunol. 2005; 174: 5781‒5788.
  11. Brenn D, Richter F, Schaible H. Sensitization of unmyelinated sensory ibers of the joint nerve to mechanical stimuli by interleukin-6 in the rat: an inlammatory mechanism of joint pain. Arth Rheum. 2007; 56 (1): 351‒359.
  12. Lila AM. Osteoartroz kolennyh sustavov: lechenie s pozicij dokazatel'noj mediciny [Osteoarthritis of the knee: treatment with evidence-based medicine]. Novye Sankt– Peterburgskie vrachebnye vedomosti [New St. Petersburg medical statements]. 2006; 1 (35): 38–44.
  13. McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non–surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014; 22 (3): 363–388. DOI: 10.1016/j.joca.2014.01.003
  14. Cvetkova ES, Lonichenok NG, Denisov LN. Sovremen-naja farmakoterapija osteoartroza kolennyh sustavov: osobennosti simptomaticheskogo i bolezn'–modifici-rujushhego dejstvija: Soobshhenie 1; Osobennosti simptomaticheskogo dejstvija sovremennyh preparatov pri osteoartroze kolennyh sustavov [Modern pharmacotherapy of osteoarthritis of the knee: features symptomatic and disease-modifying effect: report 1; Features symptomatic action of modern drugs for osteoarthritis of the knee]. Nauchno–prakticheskaja revmatologija [Scientifc and practical rheumatology]. 2015; 53 (1): 63–68.
  15. Towheed TE, Maxwell L, Anastassiades TP, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005; 18 (2): 2946.
  16. Reichenbach S, Sterchi R, Scherer M, et al. Meta–analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med. 2007; 146 (8): 580–590. DOI: 10.7326/0003–4819– 146–8–200704170–00009.

 

PDF downloadEvaluation of endothelial dysfunction of the feto-placental complex in premature abruption of normally positioned placenta

UDC 618.36-007.281-039.11-07

DOI: 10.20969/vskm.2016.9(1).51-57

PAKHOMOVA ZHANNA E., D. Med. Sci., professor, city maternity facility № 6, republic of Uzbekistan, 100047, Tashkent, Shahrisabski str., 83, tel. (+9-98-71)-236-27-62, e-mail: pahomovaje@mail.ru

KOMILOVA MASTURA S., senior research worker, city maternity facility № 6, republic of Uzbekistan, 100047, Tashkent, Shahrisabski str., 83, tel. (+9-98-71)-236-27-62, e-mail: pahomovaje@mail.ru

Abstract. Aim — to study a character of endothelial dysfunction in the fetoplacental complex in premature abruption of normally positioned placenta (PANPP) in pregnant women without hypertensive syndrome. Material and methods. We followed-up 67 pregnant women with a term of gestation of 28—41 weeks with PANPP and without a hypertensive syndrome and their newborns. Group 1 comprised 35 primapara Group 2—32 multipara women and Group 3 (a control group) included 20 healthy pregnant women with a physiological course of pregnancy. ELIZA method was used to test the blood of pregnant women and their newborns for ET-1, VEGF, PLGF, IL-1β, IL-6, IL-10, TNF-α. Results and discussion. Pregnant women with PANPP had infammatory diseases of the small pelvis organs, viz. chlamydias, HSV, CMV in 25 (37,3%), ureaplasma — in 51 (76,1%). Abortion threat took place in 32 (47,8%), vomiting of pregnant — in 16 (23,9%), acute respiratory infections — in 39 (58,2%), fetoplacental insuffciency — in 31 (46,3%). On examination a rise in ET-1, VEGF and a decrease in PLGF was noted in the blood of pregnant women with PANPP in comparison with healthy pregnant women suggesting on an endothelium lesion in the uterus and placenta vascular walls, possibly, promoting a manifestation of PANPP clinic. Evaluation of prognostic value of endothelial dysfunction showed (ET-1, VEGF, PLGF) high sensitivity, specifcity and accuracy. It was also found that the blood of pregnant women had increased cytokines in comparison with the control group: IL-1β was 2,7—3,0 times higher; IL-6 — 7,3—8,0 times higher; TNF-α — 2,4—2,6 times higher and there was a 1,4—1,5 fold fall in IL-10. Conclusion. Thus, the fetoplacental system is self-regulated. In development of endothelial dysfunction processes of decompensation occur and fetoplacental system cannot continue its self-provision and then various complications happen, such as a disorder the uterine placental-fetal blood fow, delay in fetal development, abortion and PANPP. Evaluation of markers of endothelial dysfunction in PANPP will provide a possibility of prognosis of placental detachment at the preclinical stage and that will enable the obstetrician to begin treatment-and-prophylactic actions in due time.

Key words: endothelial dysfunction markers, cytokines, placental detachment.

For reference: Pakhomova ZHE, Komilova MS. Evaluation of endothelial dysfunction of the fetoplacental complex in premature abruption of normally positioned placenta. The Bulletin of Contemporary Clinical Medicine. 2016; 9 (1): 51—57.

 

References

  1. Van'ko LV, Safronova BF, Matveeva NK, Suhih GL. Oksidativnyj stress v geneze akusherskih oslozhnenij [An oxidative stress in genesis of obstetric complications]. M: GEHOTAR-Media. 2010; 264 p.
  2. Barinov SV, Rogova EV, Kadcyna TV, SHamina IV. Prognozirovanie placentarnoj nedostatochnosti pri mnogoplodnoj beremennosti na osnovanii opredeleniya faktora rosta placenty [Forecasting of placentary insuffciency at polycarpous pregnancy on the basis of defnition of a factor of growth of a placenta]. Akush I gin [Obstet and Gynecol]. 2015; 7: 43–47.
  3. Volkova EV, Kopylova YUV. Rol' sosudistyh faktorovrosta v patogeneze placentarnoj nedostatochnosti [Rol of vascular factors of growth in pathogenesis of placentary insuffciency]. Akusherstvo Ginekologiya Reprodukciya [Obstet Gynecol Reprod J]. 2013; 2: 29–33.
  4. Lipatov IS, Tezikov YUV. Prognozirovaniei diagnostika placentarnoj nedostatochnosti na osnove markerov ehndotelial'noj disfunkcii, decidualizacii, apoptoza I kletochnoj proliferacii [Forecasting and diagnostics of placentary insuffciency on the basis of markers of ehndotelialny dysfunction, a detsidualization, apoptosis and cellular proliferation]. Saratovskijnauchn–med Zhurn [Saratov Journal of Medical Scientific]. 2011; 7 (1): 52–59.
  5. Nevzorova IA, Egorova AT, Salmina AB, ZHirova NV. Rol' markerov ehndotelial'noj disfunkcii v diagnostike otslojki horiona [Rol of markers of endotelialny dysfunction in diagnostics of an otsloyka of a horion]. Vopr ginek, akush i perinat [Gynecol, Obstet and Perinatol]. 2014; 6 (13): 49–53.
  6. Makarov OV, Volkova EN, Dzhohadze LS. Perspektivy diagnostiki I prognozirovaniya preehklampsii [Prospects of diagnostics and forecasting of a preeklampsiya]. Ross vestn akush–gin [Russian Bulletin of Obstetrican– gynaecologist]. 2012; 1: 35–42.
  7. Sidorova IS, Nikitina NA, Unanyan AL, Rzaeva AA, Kinyakin VV. Ocenka effektivnosti terapii preehklampsii v zavisimosti ot tyazhesti gestacionnoj disfunkcii ehndoteliya [Otsenka of effciency of therapy of a preeklampsiya depending on weight of gestational dysfunction an endoteliya]. Ross vestn akush–gin [Russian Bulletin of Obstetrican–gynaecologist]. 2013; 3: 4–8.
  8. Rogova EV, Barinov SV, Dolgih TI, Savel'eva IV. Znachenie faktora rosta placenty v geneze oslozhnenij pri mnogoplodnoj beremennosti [Znacheniye of a factor of growth of a placenta in genesis of complications at polycarpous pregnancy]. Ross vestn akush–gin [Russian Bulletin of Obstetrican–gynaecologist]. 2012; 6: 7–9.
  9. Savel'eva IV, Barinov SV, Rogova EV. Rol' faktorarosta v prognoze razvitiya tyazhelyh gestacionnye oslozhnenij u beremennyh s metabolicheskim sindromom [Rol of growth factor in the forecast of development heavy gestational complications at pregnant women with a metabolic syndrome]. Ross vestn akush–gin [Russian Bulletin of Obstetrican–gynaecologist]. 2012; 1: 16–19.
  10. Lomova NA, Ordzhonikidze NV, Van'ko LV. Sindrom sistemnogo vospalitel'nogo otveta I beremennost'
    (obzorliteratury) [Sindr of the system infammatory answer and pregnancy (review of literature)]. Akush i gin [Obstet and Gynecol]. 2012; 1: 23–27.
  11. Suhih ET, Van'ko LV. Immunnye faktory v ehtiologii i patogeneze oslozhnennoj beremennosti [Immune factors in an etiology and pathogenesis of the complicated pregnancy]. Akush i gin [Obstet and Gynecol]. – 2012; 1: 128–136.
  12. Burdon С., Mann С., Cindrova–Davies Т. et al. Oxidative stress and the induction of cyclooxygenase enzymes and apoptosis in the murine placenta. Placenta. 2007; 28 (7): 724–733.
  13. Tikvica A, Kusan Jukic M, Pintaric I et al. Nitric oxide synthesis in placenta is increased in intrauterine growth restriction and fetal hypoxia. Coll Antropol. 2008; 32(2): 565–570.
  14. Wang A. Preeclampsia: role of angiogenic factors in its pathogenesis. Physiology (Bethesda). 2009; l24: 147–158.
  15. Forbes K, Westwood M. Maternal growth factor regulation of human placental development and fetal growth. J Endocrinol. 2010; 207 (1): 1–16.
  16. Lamarca B. The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia. J Minerva Ginecol. 2010; 62 (2): 105–120.
  17. Peltier MR, Faux DS, Hamblin SD et al. Cytokine production by peripheral blood mononuclear cells of women with a history of preterm birth. J Reprod Immunol. 2010; 84 (1): 111–116.
  18. Lamarca B. Endothelial dysfunction. An important mediator in the pathophysiology of hypertension during pre– eclampsia. J Minerva Ginecol. 2012; 64 (4): 309–320.
  19. George EM, Granger J P. Endothelin: key mediator of hypertension in preeclampsia. Am J Hypertens. 2011; 24 (9): 964–969.
  20. Ekman-Ordeberg G, Dubicke A. Preterm Cervical Ripening in humans. Facts Views Vis Obgyn. 2012; 4 (4): 245–253.

 

PDF downloadExercise performance and indexes of cardiopulmonary exercise testing in healthy smoking and nonsmoking young men 

UDC 612.2:613.84

DOI: 10.20969/vskm.2016.9(1).57-63

POSTNIKOVA LARISA B., D. Med. Sci., associate professor, chief freelance pulmonologist of Ministry of Health care of the nizhniy novgorod region, Head of Municipal advisory pulmonology center of city hospital № 28, Russia, Nizhniy Novgorod, e-mail: th@mail.ru">plbreаth@mail.ru

DOROVSKOY IVAN A., physician of city clinical hospital № 38, Russia, Nizhniy Novgorod, e-mail: fiatlux2008@rambler.ru

KOSTROV VLADIMIR A., c. Med. Sci., associate professor, consultant, pulmonologist of city hospital № 28, Russia, Nizhniy Novgorod

DOLBIN IGOR V., D. Med. Sci., associate professor, consultant, cardiologist of city clinical hospital № 38, Russia, Nizhniy Novgorod

GUDIM ANDREI L., physician of city clinical hospital № 38, Russia, Nizhniy Novgorod

Abstract. Aim. To study the level of physical activity and indices of cardiopulmonary exercise testing (CPET) in healthy smoking and non-smoking young men. Material and methods. Physical activity and parameters of cardiopulmonary exercise testing (CPET) studied of 130 healthy non-smoking young men and 29 smokers. The CPET performed using the complex Quark CPET «COSMED» (Italy) and used a modifed Bruce Protocol. Results and discussion. Comparative analysis of physical ftness in smokers and non-smoking young men showed a signifcant decrease in physical endurance. The 68,97% smoking men passed the exercise «Run 1000 meters» to rating «3». Non-smokers men had a rating of «3» for this exercise only in 22,31% of cases. The rating «excellent» had a non-Smoking young person is 4 times more often. Active smokers men had a signifcant decrease of maximal tidal volume (VTmax) (p=0,02). The other parameters CPET had no statistically signifcant differences between groups. Conclusion. In healthy young men signifcantly reduces physical endurance. The decrease of VTmax in healthy young smokers may indicate a limitation of lung function reserves. The modifed Bruce Protocol for conducting CSTP can be recommended for screening young healthy men to identify functional disorders of the respiratory system.

Key words: young healthy men, smoking, cardiopulmonary exercise testing, gas analysis, maximum consumption of oxygen.

For reference: Postnikova LB, Dorovskoy IA, Kostrov VA, Dolbin IV, Gudim AL. Exercise performance and indexes of cardiopulmonary exercise testing in healthy smoking and non-smoking young men. The Bulletin of Contemporary Clinical Medicine. 2016; 9 (1): 57—63.

 

References

  1. World Health Organization Regional Offce for Europe. A European framework to promote physical activity for health. 2007; 47: 5–6.
  2. Bojcov SA. Okazanie medicinskoj pomoshhi vzroslomu naseleniju po optimizacii fzicheskoj aktivnosti [Providing medical assistance to adults to optimize the physical activity]. Metodicheskie rekomendacii — Moskva [Guidelines — Moscow]. 2012; 33 p.
  3. Kerbikov OB, Aver'janov AV, Borskaja EN, Krutova TV. Kardiopul'monal'noe nagruzochnoe testirovanie v klinicheskoj praktike [Cardiopulmonary exercise testing in clinical practice]. Zhurnal klinicheskaja praktika [Journal of Clinical Practice]. 2012; 2: 58–70.
  4. Balady GJ, Arena R, Sietsema K, et al. Clinician's Guide to Cardiopulmonary Exercise Testing in Adults: A Scientifc Statement From the American Heart Association. 2010; 122: 191–225.
  5. Tokaeva LK, Pavlenkovich SS. Fizicheskaja rabotosposobnost' kak integral'nyj pokazatel' funkcional'nogo sostojanija i zdorov'ja studentov pedagogicheskogo VUZa [Physical performance as an integral indicator of the functional state of health of students and teachers of the university]. Izvestija Penzenskogo gosudarstvennogo pedagogicheskogo universiteta im VG Belinskogo [News of Penza State Pedagogical University VG Belinsky]. 2011; 25: 645–649.
  6. Mustafina MH, Chernjak AV. Kardiorespiratornyj nagruzochnyj test [Cardiorespiratory exercise test]. Zhurnal atmosfera: Pul'monologija i allergologija [Journal atmosphere: Pulmonology and Allergology]. 2013; 3: 56–62.
  7. Mezzania A, Agostonib P, Cohen-Solald A. Standards for the use of cardiopulmonary exercise testing for the functional evaluation of cardiac patients: a report from the Exercise Physiology Section of the European Association for Cardiovascular Prevention and Rehabilitation European tion. Journal of Cardiovascular Prevention and Rehabilita. 2009; 16: 249–267.
  8. Tavrovskaja TV. Velojergometrija: prakticheskoe posobie dlja vrachej [Veloergometry: a Practical Guide for doctors]. SPb: Medicinskaja literatura [St Petersburg: Medical literature]. 2007; 4–71.

 

PDF downloadDevelopment and implementation of computerized data management systems for assessment of diabetic foot outpatient treatment efficacy 

УДК 617.586-002.44-02:616.379-008.64

DOI: 10.20969/vskm.2016.9(1).64-70

UDOVICHENKO OLEG V., c. Med. Sci., endocrinologist of the Diabetic foot clinic of city policlinic № 22, russia, Moscow, e-mail: ovu2003@mail.ru

BERSENEVA EVGENIA A., D. Med. Sci., Head of the Department of information technologies in health care of Semashko national research institute of Public Health, russia, Moscow, e-mail: eberseneva@gkb-31.ru MESHKOV DMITRY O., D. Med. Sci., Head of sector of coordination of scientific researches of Semashko national research institute of Public Health, russia, Moscow, e-mail: meshkovdo@nriph.ru

Abstract. Quality control of treatment results is an actual problem in outpatient settings. This task is accomplished by necessity to develop specifc criteria and indicators of effcacy for every disease. Aim. Elaboration of (1) methods of data collection in feld of diabetic foot outpatient treatment and of (2) algorithms for automated calculation of key performance indicators. Material and methods. We performed analysis of everyday clinical practice and experts’ guidelines concerning treatment of diabetic foot. Results. We developed an algorithm for a computerized system using data from outpatient diabetic foot clinic (DFC) patients’ registry for calculation of key indicators of treatment effcacy. Conclusions. Calculation of effcacy indicators for outpatient treatment in DFC requires maintaining of registry of DFC patients. This developed algorithm allows to calculate these indicators automatically. This algorithm can be also applied to assessment of treatment effcacy of other diseases with chronic course but principal curability.

Key words: computerized data management system, quality control, treatment results, calculation algorithm, treatment effcacy, diabetic foot, diabetes mellitus.

For reference: Udovichenko OV, Berseneva EA, Meshkov DO. Development and implementation of computerized data management systems for assessment of Diabetic foot outpatient treatment effcacy. The Bulletin of Contemporary Clinical Medicine. 2016; 9 (1): 64—70.

 

References

  1. Shchepin OP, Starodubov VI, Lindenbraten AL, Galanova GI. Metodologicheskie osnovy i mekhanizmy obespecheniya kachestva meditsinskoy pomoshchi [Methodological bases and mechanisms of ensuring quality of medical care]. Moscow: Meditsina [Moscow: Medicine]. 2002; 176 p.
  2. Vyalkov AI, Kucherenko VZ, Vardosanidze SL, Yakovlev EP, Vyalkova GM, Ekkert NV Upravlenie kachestvom meditsinskoy pomoshchi [Quality management of medical care]. Glavvrach [Chief doctor]. 2007; 10: 18-25.
  3. Shchepin OP. Sovremennye podkhody k upravleniyu kachestvom meditsinskoy pomoshchi na razlichnykh ierarkhicheskikh urovnyakh [Modern approaches to quality management of medical care at various hierarchical levels]. Moscow: National Research Center of Public Health, 2012; 162 p.
  4. Donabendian A. Evaluating the quality of medical care. Milbank Mem Fund Q. 1966; 44 (3): 166-206.
  5. Jeffcoate WJ, Chipchase SY, Ince P, Game FL. Assessing the Outcome of the Management of Diabetic Foot Ulcers Using Ulcer-Related and Person-Related Measures. Diabetes Care. 2006; 29 (8): 1784-1787.
  6. International Working Group on the Diabetic Foot (IWGDF). International Consensus on the Diabetic Foot. Amsterdam. 1999; 96 p.
  7. Maximova NV. Kliniko-ekonomicheskiy analiz konser-vativnoy taktiki lecheniya patsientov s sindromom diabeticheskoy stopy v gorode Moskve [Clinical and econmic analysis of conservative tactics of treatment of patients with diabetic foot in the city of Moscow]. Thesis of the PhD dissertation, Moscow. 2011; 42 p.
  8. Udovichenko OV, Berseneva EA. Effektivnost' ambu-latornogo lecheniya sindroma diabeticheskoy stopy v povsednevnoy praktike kabineta «Diabeticheskaya stopa»: kogortnoe issledovanie [Effcacy of outpatient treatment of diabetic foot patients in routine practice of a diabetic foot clinic: a cohort study]. Sakharnyy diabet [Diabetes mellitus]. 2014; 3: 107-112.
  9. Astsatryan L, Shiriptsyngeeva T, Udovichenko O. First experience with voluntary audit of diabetic foot clinics in Russia. Abstractbook of the 12th Meeting of the EASD Diabetic Foot Study Group (12-14 September, Bratislava, Slovakia). 2014; 0-4.

 

PDF downloadPossibility of early diagnosis of bone metabolism disorders in postmenopausal women

UDC [616.71-007.234:618.173]-074

DOI: 10.20969/vskm.2016.9(1).71-74

CHEPURNENKO SVETLANA A., D. Med. Sci., cardiologist of cardiosurgery center of rostov regional clinical hospital, assistant of professor of the Department of general and clinical biochemistry with a course of organic and inorganic chemistry № 1 of Rostov State Medical university, Russia, 344022, Rostov-on-Don, Nakhichevan lane, 29, e- mail: ch.svet2013@yandex.ru

MIKASHINOVICH ZOYA I., D. Biol. Sci., professor, Head of the Department of general and clinical biochemistry № 1 of Rostov State Medical university, Russia, 344022, Rostov-on-Don, Nakhichevan lane, 29

BULGAKOVA NATALIA M., c. Med. Sci., cardiologist of cardiosurgery center of Rostov regional clinical hospital, Russia, 344000, Rostov-on-Don, Blagodatnaya str., 170

Abstract. Aim. Assessing the prevalence of disorders of bone metabolism in postmenopausal women using laboratory methods and identify modifable pathogenetic factors that slow the progression of osteoporosis. Material and methods. Parameters of bone metabolism were evaluated in 52 patients aged (66±7,17) years. The content of β-SrossLaps, parathyroid hormone (PTH), total vitamin D and estradiol in blood was measured in the automated analyzer «Roch Cobas e 602» manufactured by Roch Diagnostics. Results and discussion. At 51,92% level of β-CrossLaps exceeded 0,400 ng/ ml, which is a determinant of severe and/or recurrent calcium stone formation associated with increased bone resorption. Defciency of vitamin D (less than 12 ng/ml) was detected in 28,85% of cases. Lack of vitamin D (12—20 ng/ml) was determined in 26,92% of cases. In 42,3% of patients the estradiol level was below 39,6 pmol/L, which was associated with a high risk of hip fractures and spinal deformity. Duration of menopause more than 10 years old are not allowed to assign the menopausal hormone therapy for 75% of patients. The average level of PTH in our sample ranged 2,99—9,57 pmol/L was (5,49±0,73) pmol/L. The 9,62% of cases were determined by secondary hyperparathyroidism. Conclusion. More than half of the surveyed patients diagnosed defciency and insuffciency of vitamin D, combined with the growth of the marker of bone resorption, which required the active drug therapy aimed at slowing down osteoporosis.

Key words: osteoporosis, β-SrossLaps, vitamin D, estradiol, parathyroid hormone.

For reference: Chepurnenko SA, Mikashinovich ZI, Bulgakova NM. Possibility of early diagnosis of bone metabolism in postmenopausal women. The Bulletin of Contemporary Clinical Medicine. 2016; 9 (1): 71—74.

 

References

  1. Arrabal-Polo MA, Arrabal-Martin М, Poyatos-Andujar А et al. Is the fasting calcium/creatinine a bone resorption marker in patients with calcium renal stones? Urological research. 2012; 40 (3): 243–245.
  2. Ross AC, Taylor CL, Yaktine AL, Del Valle HB. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academy Press (US). 2010; 662 p.
  3. Arrabal-Polo MA, Arrabal–Martin M, de Haro–Munoz Т et al. Mineral density and bone remodelling markers in patients with calcium lithiasis. BJU international. 2011; 108 (11): 1903–1908.
  4. Bozic B, Loncar G, Prodanovic N et al. Relationship between high circulating adiponectin with bone mineral density and bone metabolism in elderly males with chronic heart failure. Journal of cardiac failure. 2010; 16 (4): 301–307.
  5. Pobeha P, Ukropec J, Skyba P et al. Relationship between osteoporosis and adipose tissue leptin and osteoprotegerin in patients with chronic obstructive pulmonary disease. Bone. 2011; 48 (5): 1008–1014.
  6. Liu G, Lu G. Diagnostic effcacy of serum β–Crosslaps and amino terminal procollagen extension propeptide (PINP) measurements for identifying postmenopausal women with osteoporosis [J]. International Journal of Laboratory Medicine. 2010; 8: 018.
  7. Rozenberg S, Lanoy E, Bentata M et al. Effect of alendronate on HIV–associated osteoporosis: a randomized, double– blind, placebo–controlled, 96–week trial (ANRS 120). AIDS research and human retroviruses. 2012; 28 (9): 972–980.
  8. Yiwei J, Zongquan L, Min S, Bin L. Experimental study of the effect of different extracts of epimedium on PINP and NTx in ovariectomized rats. Chinese Journal of Osteoporosis. 2014; 20 (2): 142.
  9. Arrabal–Polo MA, Arrabal–Martin M, de Haro–Muñoz T et al. Biochemical determinants of severe lithogenic activity in patients with idiopathic calcium nephrolithiasis. Urology. 2012; 79 (1): 48–54.
  10. Povoroznyuk VV, Grigor'eva NV. Menopauza i osteoporoz [Menopause and Osteoporosis]. Reproductive Endocrinology. 2012; 2 (4): 40–47.
  11. Kroll MH, Bi C, Garber CC et al. Temporal relationship between vitamin D status and parathyroid hormone in the United States. PloS one. 2015; 3: URL: http://journals.plos. org/plosone/article?id=10.1371/journal.pone.0118108
  12. Pleshcheva AV, Pigarova EA, Dzeranova LK. Vitamin D i metabolizm: fakty, mify i predubezhdeniya [Vitamin D and metabolism: facts, myths and prejudices]. Ozhirenie i metabolism [Obesity and Metabolism]. 2012; 2: 33–42.
  13. Pilz S, Tomaschitz A, Drechsler C et al. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. European heart journal. 2010; 31: 1591–1598.
  14. Chen WR, Chen YD, Shi Y et al. Vitamin D, parathyroid hormone and risk factors for coronary artery disease in an elderly Chinese population. Journal of Cardiovascular Medicine. 2015; 16 (1): 59–68.
  15. Kestenbaum B, Katz R, de Boer I et al. Vitamin D, parathyroid hormone, and cardiovascular events among older adults. Journal of the American College of Cardiology. 2011; 58 (14): 1433–1441.
  16. Kanis JA, Johnell O, Oden A et al. FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporosis International. 2008; 19 (4): 385–397.

 

 

PDF downloadPrevalence of anxiety and depressive disorders among workers of workers of metallurgical enter-prises with arterial hypertension

UDC 616.8-008.64:616.12-008.331.1

DOI: 10.20969/vskm.2016.9(1).75-79

CHIGISOVA ANTONINA N., junior research worker of the laboratory of epidemiology of cardiovascular Disease research
institute of complex problems of cardiovascular disease, Russia, 650002, Kemerovo, Sosnovyj blvd., 6, tel. 8-960-916-40-93,
e-mail: chigan@kemcardio.ru

OGARKOV MIKHAIL YU., D. Med. Sci., professor, Head of the Department of cardiology of novokuznetsk State institute
of Advanced Medical, Head of the laboratory of epidemiology of cardiovascular Disease research institute of complex
problems of cardiovascular disease, Russia, 650002, Kemerovo, Sosnovyj blvd., 6, tel. 8-905-900-93-80,
e-mail: ogarmu@kemcardio.ru

SCRIPCHENCO ALLA E., c. Med. Sci., associate professor of the Department of cardiology of novokuznetsk State
institute of Advanced Medical, senior research worker of the laboratory of epidemiology of cardiovascular Disease
research institute of complex problems of cardiovascular disease, Russia, 650002, Kemerovo, Sosnovyj blvd., 6,
tel. 8-903-909-79-60, e-mail: scripae@kemcardio.ru

Abstract. The purpose of research — to study the prevalence of anxiety and depression among workers of metallurgical enterprises and their association with the incidence of hypertension. Material and methods. A total of 1,285 people working in harmful conditions of manufacture. To inspect, survey (age, sex, risk factors), blood pressure measurement, testing was used to identify the level of anxiety and depression. Results and discussion. The population was characterized by a high incidence of metallurgists hypertension, low blood pressure control, as well as high levels of anxiety and depression among men — women. The presence of depressive symptoms in the female population was associated with hypertension. Conclusion. Among the workers of the metallurgical enterprise established sex differences in the prevalence of anxiety and depressive disorders: prevalence of anxiety among men, among women — depression. The presence of depression was associated with a greater prevalence of hypertension in the female population.

Key words: hypertension, anxiety and depressive disorders.

For reference: Chigisova AN, Ogarkov MY, Scripcenco AE. Prevalence of anxiety and depressive disorders among workers of workers of metallurgical enterprises with arterial hypertension. The Bulletin of Contemporary Clinical Medicine. 2016; 9 (1): 75—79.

 

References

  1. Krasnov VN. Obrazovatel'naja programma po depres-sivnym rasstrojstvam [Educational program for depressive disorders]. M: MNII Psihiatrii. 2010; 2 ( Depressija i somaticheskie zabolevanija [Depression and physical illness] ): 49–50.
  2. Datieva AJu, Astahova ZT. Faktory riska ishemicheskoj bolezni serdca u zhenshhin, prozhivajushhih v Rso–Alanija [Risk factors for coronary heart disease in women living in the North Ossetia–Alania]. Medicinskie nauki [Medical sciences]. 2015; 1: 1345–1348.
  3. Fusu LI. Jepidemiologicheskie osobennosti psihosoma-ticheskih i depressivnyh rasstrojstv v evropejskoj populjacii [Epidemiological features of psychosomatic and depressive disorders in the European population]. Nevrologija, nejropsihiatija, psihosomatika [Neurology, neyropsihiatiya, Psychosomatics]. 2012; 4: 14–17.
  4. Muhtarenko SJu, Murataliev TM et al. Affektivnye rasstrojstva, kachestvo zhizni i priverzhennost' k lecheniju u bol'nyh koronarnoj bolezn'ju serdca pri razlichnyh
    metodah lechenija [Affective disorders, quality of life and adherence to treatment in patients with coronary heart disease with different treatments]. Vestnik KRSU [Bulletin KRSU]. 2014; 14 (5): 118–122.
  5. Kiseleva MG. Psihologicheskie faktory i techenie serdechno–sosudistyh zabolevanij [Psychological factors and course of cardiovascular diseases]. Nacional'nyj psihologicheskij zhurnal [National Psychological Journal]. 2012; 1 (7): 124–130.
  6. Antonysheva OV, Kozlovskij VI. Profl' lichnosti, trevozhnye i depressivnye rasstrojstva u bol'nyh arterial'noj giper-tenziej [Personality profile, anxiety and depressive disorders in hypertensive patients]. Vestnik Vitebskogo gosudarstvennogo medicinskogo universiteta [Journal of Vitebsk State Medical University]. 2010; 9 (2): 1–8.
  7. Aleksandrovskij JuA. Predboleznennye sostojanija i pogranichnye psihicheskie rasstrojstva [Premorbid state and borderline mental disorders]. M: Litterra. 2010; 165–171.
  8. Kel'man G P, Ustinova OJu et al. Vlijanie uslovij truda i social'nyh faktorov na razvitie proizvodstvenno obuslovlennoj patologii u rabotnikov metallurgicheskoj promyshlennosti [Infuence of working conditions and social factors on the development of work–related diseases among workers of metallurgical industry]. Izvestija Samarskogo nauchnogo centra Rossijskoj akademii nauk [Proceedings of the Samara Scientifc Center of the Russian Academy of Sciences]. 2012; 14 (5, 3): 668–671.
  9. Gluhanjuk NS, D'jachenko EV, Semenova SL. Praktikum po obshhej psihologii: uchebnoe posobie [Workshop on General Psychology: Textbook]. Voronezh: NPO «MODJeK». 2006; 224 р.
  10. Bojcov SA, Balanova JuA, Shal'nova SA et al. Arterial'naja gipertonija sredi lic 25–64 let: rasprostranennost', osvedomlennost', lechenie i kontrol': po materialam issledovanija JeSSE [Arterial hypertension among people aged 25–64: prevalence, awareness, treatment and control: based on materials research of ESSE–RF]. Kardiovaskuljarnaja terapija i proflaktika [Cardiovascular therapy and prevention]. 2014; 13 (4): 4–14.
  11. Filippov EV, Jakushin SS. Rasprostranennost' arterial'noj gipertonii i osobennosti vedenija bol'nyh s arterial'noj gipertoniej i razlichnym riskom serdechno–sosudistyh oslozhnenij (Po dannym issledovanija MERIDIAN–RO) [The prevalence of hypertension and characteristics of patients with hypertension and the risk of various cardiovascular complications (According to a study MERIDIAN–RO)]. Medicinskij sovet [Medical advice]. 2013; 9: 65–69.
  12. Dobrovol'skij AB, Titaeva EV et al. D–dimer, fbrinogen i uroven' arterial'nogo davlenija: analiz populjacii vzroslogo naselenija Tomska (issledovanie JeSSE–RF) [D–dimer, fbrinogen, and blood pressure: analysis of the adult population of Tomsk (research of ESSE–RF)]. Aterotromboz: specializirovannyj medicinskij zhurnal [Atherothrombosis: specialized Medical Journal]. 2014; 2: 19–24.
  13. Shal'nova SA, Evstifeeva SE, Deev AD, Artamo-nova GV et al. Rasprostranennost' trevogi i depres-sii v razlichnyh regionah Rossijskoj Federacii i ee associacii s social'no–demograficheskimi faktorami (po dannym issledovanija JeSSE–RF) [The prevalence of anxiety and depression in different regions of the Russian Federation and its association with socio– demographic factors (according to research of ESSE– RF)]. Terapevticheskij arhiv [Therapeutic Archives]. 2014; 12: 52–59.
  14. Taratenko LA, Maljutina NN. Kachestvo zhizni rabotnikov himicheskogo proizvostva metanola i formal'degida [The quality of life of workers of chemical proizvostvo methanol and formaldehyde]. Medicinskie nauki [Medical sciences]. 2012; 2: URL: http://www.science–education. ru/102–6102 15. Gafarov VV, Panov DO, Gromova EA, Gagulin IV, Gafarova AV. Svjaz' lichnostnoj trevozhnosti s informirovannost'ju o svoem zdorov'e i ee vlijanie na 16–letnij risk razvitija ostryh
    serdechno–sosudistyh zabolevanij v otkrytoj populjacii sredi zhenshhin 25–64 let [Communication of personal anxiety with awareness of your health and its impact on the 16–year risk of acute cardiovascular disease in the open population of women 25–64 years old]. Rossijskij kardiologicheskij zhurnal [Russian Cardiology Journal]. 2014; 8 (112): 63–67.

 

 

PDF downloadChronic obstructive pulmonary disease in patients cardiology: problems of diagnosis and treatment

 UDC 616.24-036.12:616.1

DOI: 10.20969/vskm.2016.9(1).79-83

SHAPOVALOVA TATIANA G., D. Med. Sci., professor of the Department of therapy, pediatric and dental faculties of V.I. Razumovskу Saratov State Medical university, Russia, Saratov, Bolshaya Kazachia str., 112, tel. 8-927-105-84-99, e-mail: t.G.Shapovalova@gmail.com

RYABOVA ANNA YU., D. Med. Sci., professor of the Department of therapy, pediatric and dental faculties of V.I. razumovskу Saratov State Medical university, Russia, Saratov, Bolshaya Kazachia str., 112, tel. 8-917-203-31-23, e-mail: anna917@bk.ru

PLASTININA ELENA S., physician of Municipal hospital № 8 of Saratov, Russia, e-mail: lenocka-08@mail.ru;

PONOMAREVA OLGA A., physician of functional diagnostic of city clinic № 11 of Saratov, Russia, e-mail: lelikpon@yandex.ru

SHELOBANOVA NATALIA V., pulmonologist of Municipal hospital № 8 of Saratov, e-mail: shelobanova-nata@list.ru

SHASHINA MARINA M., c. Med. Sci., associate professor of the Department of therapy pediatric and dental faculties of V.I. razumovskу Saratov State Medical university, e-mail: maric56@mail.ru

ZAKIROVA VENERA B., c. Med. Sci., cardiologistofinternationalclinicDiagnosticcentre, Russia, Kazan, Karbishevstr., 12A, e-mail: vzakirova@bk.ru

Abstract. Cardiovascular (CV) diseases represent a common comorbidity among COPD patients. CV comorbidities increase the rate of mortality 2—5 fold in COPD patient population. Aim of study. Detection of COPD among patients hospitalized in a CV department of a multi-profle hospital. Material and methods. Evaluation of COPD risk factors among patients hospitalized in CV department. Evaluation of effcacy of maintenance therapy in patients with confrmed COPD diagnosis. Results. Pts hospitalized in CV departments by using a questionnaire for evaluation of COPD symptoms. FEV1 was measured for patients with confrmed risk factors for COPD. Severity of dyspnea was evaluated by mMRC scale. Post-bronchodilator FEV1 was assessed in patients with signifcant COPD risk factors and FEV1<80% predicted (pre-bronchodilator values). Dyspnea score was signifcantly higher in patients with CV comorbidities (p<0,05). 29 patients had increased risk of developing COPD, smoking index >10 pack years. Of those 20 patients had FEV1/FVC<80%, although only 8 (7,7%) were previously diagnosed with COPD. Spirometry data analysis showed that 7 patients had airfow obstruction stage GOLDI and 13 pts — GOLDII. In this group COPD was present with the following comorbidities: arterial hypertension stage II-III (7pts), myocardial infarction (9 pts), unstable angina (1 pt), effort angina (3 pts). 13 pts had mMRC≥2 and 7 pts mMRC<2. Exacerbation risk was higher in 6 pts previously diagnosed with COPD. Conclusion. We found insuffcient detection of early-stage CODP in pts hospitalized in CV departments.

Key words: COPD, сardio-vascular disease, spirometry, CV departments.

For reference: Shapovalova TG, Ryabova AYu, Plastinina ES, Ponomareva OA, Shelobanova NV, Shashina MM, Zakirova VB. Chronic obstructive pulmonary disease in patients cardiology: problems of diagnosis and treatment. The Bulletin of Contemporary Clinical Medicine. 2016; 9 (1): 79—83.

 

References

  1. Globalnaya strategiya diagnostiki, lecheniyai proflactiki chronicheskoy obstructivnoy bolesni leghich [The global strategy of the diagnosis, treatment and prevention of chronic obstructive pulmonary disease], revision of the
    2011.  M, Russian Respiratory Society. 2012; 78 p.
  2. Ahmineeva AK, Polunina OS, Sevostyanova IV, Voronina LP. Patogeneticheskie osobennosti disfunkcii endoteliya prirespiratorno-cardialinoy comorbidnosti [Pathogenic features of endothelial dysfunction in respiratory cardiac comorbidity]. Kubanskij nauchno-medicinskij vestnik [Cuban scientifc and medical Gazette]. 2014; 4: 11-15.
  3. Chuchalin AG. Chronicheskaya obstructivnaya bolesn leghix i soputstvuuychie zabolevaniya [Chronic obstructive pulmonary disease and related diseases], chast 1 CHOBL i porageniye serdechno-sosudistoy sistemy [Part 1 of COPD and the defeat of the cardiovascular system]. Rossijskij medicinskij zhurnal [Russian Medical Journal]. 2008; 5: 246-249.
  4. Sidney S, Sorel M, Quesenberry CP Jr, DeLuise C, Lanes S, Eisner MD. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest. 2005; 128: 2068-2075.
  5. Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc. 2008 May 1; 5 (4): 549-555.
  6. Federalnye clinicheskie recomendacii po diagnostici i lecheniyu chronichescoy obstructivnoy bolesni leghich [Federal clinical guidelines for diagnosis and treatment of chronic obstructive pulmonary disease]. 2013; www. pulmonology.ru
  7. Anthonisen NR, Connett JE, Murray RP, et al. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med. 2002; 166: 675-679.
  8. Ryabova AY, Shapovalova TG, Shashina MM. Osobennosti remodelirovaniya serdca pri CHOBL s soputstvuuychey serdechno-sosudistoy patologiey na phone raslichnog omedicamentoznogo phona [Features of cardiac remodeling in COPD with associated cardiovascular disease against the background of various medical backgrounds]. Recept [Recipe]. 2012; 1: 88-94.
  9. Beeh KM. The Short, the Long, and the «Ultra-long»: Why Duration of Bronchodilator Action Matters in Chronic Obstructive Pulmonary Disease. Adv Ther. 2010; 27 (3): 150-159.

 

PDF downloadThe effectiveness of proactive telephone support in smoking cessation

УДК 613.84

DOI: 10.20969/vskm.2016.9(1).83-86

YABLONSKY PETR K., D. Med. Sci., professor, director of St. Petersburg research institute of phthisiopulmonology, Russia, St. Petersburg, tel. 8-812-579-25-54, e-mail: spbniif_all@mail.ru

SUKHOVSKAYA OLGA A.   D. Biol. Sci., Head of the advisory call center for tobacco consumption quitting of St. Petersburg research institute of phthisiopulmonology, Russia, St. Petersburg, tel. 8-800-200-0-200, e-mail: ktc01@mail.ru

Abstract. Aim. The article analyzes the effectiveness of the proactive telephone help in quit smoking depending on gender, age, medical and social factors, smoking status. Material and methods. There were analyzed calls on the «hot line» (8 800 200 0 200) from 27069 smokers: the number of cigarettes per day, the age of onset of smoking, duration of smoking, the motivation to quit smoking, the degree of nicotine dependence by test Fagerstrom, the levels of anxiety and depression (Hospital Anxiety and Depression Scale). Results and discussion. Among the people who called for help in quitting smoking, 12293 smokers agreed to a monthly — proactive counseling (45,4%). The high degree of nicotine dependence, the number of cigarettes smoked per day, low level of motivation to quit smoking were factors reducing the duration of tobacco abstinence. The effectiveness of smoking cessation during cognitive-behavioral therapy by telephone interview did not depend on age, sex, duration of smoking. Conclusion. Telephone counseling for quit smoking is a popular type of care in the Russian Federation, especially in the age group 18—35 years.

Key words: smoking, telephone counseling, smoking cessation.

For reference: Yablonsky PK, Sukhovskaya OA. The effectiveness of proactive telephone support in smoking cessation. The Bulletin of Contemporary Clinical Medicine. 2016; 9 (1): 83—86.

 

References

  1. Borland R, Segan CJ, Livingston PM, Owen N. The effectiveness of callback counselling for smoking cessation: a randomized trial. Addiction. 2001; 96 (6): 881–889.
  2. Rasmussen SR. The cost effectiveness of telephone counselling to aid smoking cessation in Denmark: a modelling study. Scand J Public Health. 2013; 41 (1): 4–10.
  3. Jablonskij PK, Sukhovskaya OA. Organizacija konsul'tativnoj telefonnoj pomoshhi pri otkaze ot tabakokurenija v Rossijskoj federacii [Organization of telephone advisory help in smoking cessation in the Russian Federation]. Zdravoohranenie Rossijskoj Federacii [Health of the Russian Federation]. 2014; 1: 30–33.